When a mole changes or looks suspicious, do adults regret having it removed — or regret watching and waiting?
If you act
Having the suspicious mole removed
10%
If you don't
Watching and waiting
27%
Percentage who later regret each choice. Bars and full ledger render below.
Health
When a mole changes or looks suspicious, do adults regret having it removed — or regret watching and waiting?
Last reviewed 2026-06-21
Evidence quality 4.0/5
Eight-dimension review score against the
quality rubric
. Each dimension scored 1–5.
D1 Source verification
4/5
D2 Source authority & independence
5/5
D3 Regret-rate accuracy
3/5
D4 Source comparability
4/5
D5 Gilovich pattern
4/5
D6 Prose quality
4/5
D7 Caveat completeness
3/5
D8 Sample quality
5/5
Average4.0/5
Proxy data — no direct regret survey exists for this decision. Rates are derived from satisfaction scores and access-barrier data rather than questions that directly asked about regret. See caveats below.
Action regret
Having the suspicious mole removed
10%
~10% recurrence or cosmetic dissatisfaction; most excised suspicious moles prove benign (≈6 excised per melanoma found)
Patients undergoing excision of melanocytic nevi
post-procedure, pooled across studies
Inaction regret
Watching and waiting
27%
27% of melanoma patients delayed presentation >3 months; 44% had not realised the change was serious (delayed-presentation proxy)
Melanoma patients, recalling pre-diagnosis delay
retrospective
% who regret this choice
Having the suspicious mole removedWatching and waiting
10%27%
inaction dominates — Inaction dominates — most regret not acting.
The decision only arises when a mole has changed or looks suspicious — leaving an ordinary stable mole alone is the right call for almost everyone, and removing every mole would be wholesale overtreatment. Once a mole is flagged, removing it rarely causes regret, but it is not free. A systematic review of 46 studies (4,201 lesions) found that surgical excision recurs in about 2% of cases and shave excision in roughly 11%, with cosmetic-satisfaction scores for surgical excision the lowest of any technique at 6.2 out of 10 — a real minority unhappy with the scar (Guo & Wang, 2026). And most suspicious moles turn out to be harmless: even consultant dermatologists excise about six benign lesions for every melanoma they find, a figure that climbs toward twenty in primary care (Sidhu et al., 2012). For most people who act, the excision will, in hindsight, have been unnecessary — the price paid for diagnostic certainty.
The watching-and-waiting side carries a heavier but rarer regret. Among people whose mole turned out to be melanoma, 27% had delayed presenting for more than three months, and 44% — the single most common barrier — had simply not realised the change was serious (O’Shea et al., 2017). A qualitative study found the mechanism plainly: changing moles are “often perceived as trivial,” patients delay to avoid “wasting the doctor’s time,” and three of four people later diagnosed with melanoma in that sample never sought help at all — their GP noticed the lesion opportunistically (Walter et al., 2010). The inaction harm is conditional: most who wait are fine, but for the minority whose mole is malignant, delay shifts the stage at diagnosis and can be fatal.
That conditionality is the whole story, and it is why these two numbers must not be read as a clean head-to-head. The action-side proxy is a cosmetic-and-recurrence rate across all excised nevi; the inaction-side proxy is a delay rate measured only among confirmed melanoma patients. They come from different populations, and the inaction figure overstates the risk for any single benign mole while understating the severity for the rare malignant one. What survives the mismatch is a direction consistent with Gilovich and Medvec’s temporal asymmetry: when a mole has genuinely changed, the people who watched and waited are more likely to look back with regret than the people who had it checked and removed — even though, for most individual moles, waiting turns out to have been harmless. The magnitude depends entirely on the base rate of malignancy in the specific lesion, which only a clinician can judge.
Sources: action
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
[1]Frontiers in Medicine (Guo & Wang 2026) — Aesthetic Techniques for Melanocytic Nevus Management: Clinical Outcomes, Cosmetic Satisfaction, and Safety — A Systematic Review and Meta-analysis
Peer-reviewed
“"[Paraphrase from systematic review — abstract] 46 studies (32 for meta-analysis) covering 4,201 lesions. Clinical clearance was 96.4% (95% CI 92.1–99.2) for surgical excision and 85.7% (95% CI 80.3–90.4) for shave excision. Recurrence ranged from 2.1% (surgical excision) to 22.7% (dermabrasion); shave excision 10.7%. Cosmetic-satisfaction scores (0–10) ranged from 6.2 (surgical excision) to 8.8 (Er:YAG laser). Overall adverse-event rates ranged from 11.2% to 34.1%."
”
Source data from
2026-01-01
Accessed
2026-06-21
Calculation
Removing a mole rarely causes outright regret, but it is not free: surgical excision leaves a scar (the lowest cosmetic-satisfaction score, 6.2/10, reflecting a real dissatisfied minority), and shave excision recurs in ~10.7% of cases, sometimes prompting re-treatment. We anchor the action-side proxy at ~10%, drawn from the recurrence and cosmetic-dissatisfaction signals as the share for whom the procedure generates a lingering negative outcome. This is a dissatisfaction/ re-treatment proxy, not a "regret" survey.
[2]Clinical and Experimental Dermatology (Sidhu et al. 2012) — The number of benign moles excised for each malignant melanoma: the number needed to treat
Peer-reviewed
Mean number needed to treat (benign lesions excised per melanoma found) was 6.3 among consultant dermatologists; 4,691 lesions over 2005–2009
Excerpt
“"[Paraphrase from abstract] In total, 4,691 lesions were examined. The overall mean NNT was 6.3, with a range of 4.9–11.3 for each of nine consultant dermatologists serving a population of 600,000. The mean NNT was 7.6 for female and 4.8 for male patients."
”
Source data from
2012-01-01
Accessed
2026-06-21
Calculation
The overtreatment frame for the action side: even in expert hands, roughly six benign moles are excised for every melanoma found (far higher in primary care, where ~20 benign lesions are removed per melanoma). Most people who have a suspicious mole removed will learn it was harmless — the excision was, in hindsight, unnecessary. This is the cost the action side trades for certainty. Not a regret rate; context for why action regret, though low, is non-zero.
Sources: inaction
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
[1]BMC Cancer (O'Shea et al. 2017) — Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study
Peer-reviewed
27% of melanoma patients (n=40 of 159) delayed presentation more than 3 months; 44% (n=66) had not realised the symptom was serious — the most common barrier
Excerpt
“"A delay of greater than 3 months was reported by 27% of patients (n = 40). ... Forty-four per cent (n = 66) had not realised that the symptom was serious, which was the most common barrier reported. ... Of the 149 patients who reported symptoms, 76% (n = 113) described a change in a pre-existing mole rather than a new mole or lesion. ... Those patients who reported 'a mole growing bigger' were more likely to have a delayed presentation (OR 2.04, 95% CI 1.14–5.08)."
”
Source data from
2017-01-04
Accessed
2026-06-21
Calculation
The inaction-regret proxy: among people whose mole turned out to be melanoma, 27% had watched and waited more than three months before presenting, and 44% had not recognised the change as serious. Watching a changing mole that proves malignant is the regretted inaction. Note the population: this is melanoma patients, not the general public — the proxy applies to the suspicious/changing-mole decision, not to leaving an unchanging benign mole alone (which carries near-zero regret and is the correct choice).
[2]BMC Family Practice (Walter et al. 2010) — Patient understanding of moles and skin cancer, and factors influencing presentation in primary care: a qualitative study
Peer-reviewed
Qualitative study (n=40): changing moles often perceived as trivial; patients delayed to avoid 'wasting the doctor's time'; three of four people later diagnosed with melanoma did not seek help — the GP noticed the lesion opportunistically
Excerpt
“"Changing moles are often perceived as trivial and not signifying possible skin cancer. ... 'I left it a couple of weeks and I just thought well, you know, I've got to be sensible about this, rather than wasting doctor's time' ... Three of four people subsequently diagnosed with melanoma did not seek help; instead, their GP opportunistically noticed the lesion."
”
Source data from
2010-08-09
Accessed
2026-06-21
Calculation
Qualitative corroboration of why watchful waiting on a changing mole is regretted in hindsight: the change is dismissed as trivial, and most melanomas in this sample were caught by the doctor rather than the patient. Provides the mechanism behind the O'Shea delay figure; does not supply the rate.
Caveats
This entry is deliberately scoped to a CHANGING or SUSPICIOUS mole, not to moles in general. Leaving an ordinary, stable, benign mole alone is the correct choice for almost everyone and carries near-zero regret — removing every mole would be mass overtreatment. The bilateral comparison only holds for a mole that has changed or looks concerning. Even so, the two sides are drawn from non-comparable populations and are construct-mismatched: the action-side ~10% is a recurrence/cosmetic-dissatisfaction proxy from nevus-excision outcome studies (Guo & Wang 2026, n=4,201 lesions), while the inaction-side 27% is a delayed-presentation rate among people whose mole was melanoma (O'Shea 2017, n=159). The inaction harm is conditional and concentrated: most suspicious moles are benign (Sidhu 2012 — roughly six benign lesions excised per melanoma found, even by specialists), so for the majority, watching and waiting ends without harm; but for the minority whose mole is malignant, delay can be severe or fatal, which is why the retrospective regret on the inaction side is heavy. No survey directly asks adults "do you regret removing that mole?" or "do you regret not getting that changing mole checked?", so both rates are proxies and the -0.17 delta is an indicative direction, not a precise estimate. Populations are UK, Australian, and pooled-international rather than US. The action side also delivers diagnostic certainty (histology) that the satisfaction figures do not price in. The inaction-dominates direction is consistent with Gilovich and Medvec's temporal-asymmetry framework, but the magnitude here turns heavily on the base rate of malignancy in the specific mole, which only a clinician can assess.
